Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, Nuclear Factor-kappa B, and Cell Cycle Progression in Non-Small Cell Lung Cancer

Erlotinib is a tyrosine kinase inhibitor approved for the treatment of patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since many tumors express wild-type (wt) epidermal growth factor receptor (EGFR) or develop...

Full description

Saved in:
Bibliographic Details
Main Authors: Tai Dermawan, Josephine Kam, Gurova, Katerina, Pink, John, Dowlati, Afshin, De, Sarmishtha, Narla, Goutham, Sharma, Neelesh, Stark, George R.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4156551/
https://ncbi.nlm.nih.gov/pubmed/25028470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0013
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items